Drug repurposing hypotheses

Cross-domain candidates discovered through literature-based discovery. Each hypothesis is a chain of evidence from peer-reviewed papers.

2123 hypotheses across 108 domain pairs (als ↔ alzheimer ↔ depression ↔ epilepsy ↔ glioblastoma ↔ heart_failure ↔ inflammatory_bowel_disease ↔ multiple_sclerosis ↔ pancreatic_cancer ↔ rheumatoid_arthritis ↔ type_2_diabetes), backed by 6574 evidence papers

Start here: 295 high-confidence hypotheses

These are hypotheses where multiple independent papers support both legs of the chain (drug → mediator and mediator → outcome) and the mediator is a specific biological entity rather than a generic pathway. They are the strongest candidates for further investigation.

857 hypotheses combine a novel literature signal with no existing clinical trial — the candidates Robertium surfaced that no one has investigated yet.

Browse by therapeutic area

Counts include hypotheses where the domain is either drug source or outcome, so a single hypothesis is counted under two domains.

Showing 0 of 0 hypotheses

# Drug Mediator Outcome Validation Score Evidence

All therapeutic domains

Browse every therapeutic area indexed in the Robertium catalog. Counts include hypotheses where the domain appears as either drug source or outcome.